ZA988675B - Amino-terminally truncated rantes as chemokine antagonists. - Google Patents

Amino-terminally truncated rantes as chemokine antagonists.

Info

Publication number
ZA988675B
ZA988675B ZA9808675A ZA988675A ZA988675B ZA 988675 B ZA988675 B ZA 988675B ZA 9808675 A ZA9808675 A ZA 9808675A ZA 988675 A ZA988675 A ZA 988675A ZA 988675 B ZA988675 B ZA 988675B
Authority
ZA
South Africa
Prior art keywords
amino
terminally truncated
chemokine antagonists
truncated rantes
rantes
Prior art date
Application number
ZA9808675A
Other languages
English (en)
Inventor
Paul Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Applied Res System Ars Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA988675(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Res System Ars Holding filed Critical Applied Res System Ars Holding
Publication of ZA988675B publication Critical patent/ZA988675B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9808675A 1997-09-29 1998-09-22 Amino-terminally truncated rantes as chemokine antagonists. ZA988675B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (fr) 1997-09-29 1997-09-29 C-C chémokine tronquée à l'aminoterminus comme antagoniste de chémokines

Publications (1)

Publication Number Publication Date
ZA988675B true ZA988675B (en) 1999-11-24

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9808676A ZA988676B (en) 1997-09-29 1998-09-22 Amino-terminally truncated MCP-2 as chemokine antagonists.
ZA9808675A ZA988675B (en) 1997-09-29 1998-09-22 Amino-terminally truncated rantes as chemokine antagonists.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA9808676A ZA988676B (en) 1997-09-29 1998-09-22 Amino-terminally truncated MCP-2 as chemokine antagonists.

Country Status (29)

Country Link
US (5) US6977071B2 (fr)
EP (6) EP0906954A1 (fr)
JP (2) JP4233214B2 (fr)
KR (2) KR100542934B1 (fr)
CN (3) CN1233415C (fr)
AR (2) AR013528A1 (fr)
AT (3) ATE263242T1 (fr)
AU (2) AU750341B2 (fr)
BG (2) BG64679B1 (fr)
BR (2) BR9812565A (fr)
CA (2) CA2305017A1 (fr)
CY (1) CY1110927T1 (fr)
CZ (2) CZ299479B6 (fr)
DE (3) DE69822856T2 (fr)
DK (3) DK1021541T3 (fr)
EA (2) EA003942B1 (fr)
EE (2) EE200000152A (fr)
ES (3) ES2287601T3 (fr)
HK (3) HK1062637A1 (fr)
HU (2) HU226414B1 (fr)
IL (2) IL135351A (fr)
NO (2) NO20001584D0 (fr)
NZ (3) NZ516027A (fr)
PL (2) PL196427B1 (fr)
PT (3) PT1439231E (fr)
SK (2) SK286439B6 (fr)
UA (2) UA73081C2 (fr)
WO (2) WO1999016877A1 (fr)
ZA (2) ZA988676B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6534626B1 (en) * 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
DE60030749T2 (de) * 1999-10-25 2007-09-20 Pharis Biotec Gmbh Prozessiertes menschliches chemokin phc-1
EP1167527A1 (fr) * 2000-06-22 2002-01-02 Euroscreen S.A. Chemokines humaines tronquées: PHC-1 et PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (fr) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation de l'inflammation a l'aide de produits du type protease
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
US7553483B2 (en) 2001-12-17 2009-06-30 Merck Serono Sa Chemokine mutants acting as chemokine antagonists
WO2004104216A2 (fr) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2011097567A1 (fr) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Essai multiplexé du rantes, variants du rantes se rapportant à une maladie, et variants du rantes se rapportant à une activité enzymatique
US9296803B2 (en) 2010-03-11 2016-03-29 Health Research, Inc. Methods and compositions containing Fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
EP3813869B1 (fr) 2018-05-28 2023-10-18 Université de Genève Inhibiteur du ccr5 pour le traitement d'un trouble neuroinflammatoire impliquant une inflammation cérébrale
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1996017935A2 (fr) * 1994-12-08 1996-06-13 Glaxo Group Limited Peptide rantes et fragments et compositions comprenant ce peptide, pour le traitement de l'inflammation
WO1997025427A1 (fr) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mpc-2)
WO1997035982A2 (fr) * 1996-03-27 1997-10-02 Icos Corporation Materiels et procedes de fabrication de proteine-5 chimiotactique monocyte
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
AR013528A1 (es) 2000-12-27
NZ516027A (en) 2003-05-30
AU750606B2 (en) 2002-07-25
CN1148447C (zh) 2004-05-05
DK1439231T3 (da) 2007-11-05
US20050201977A1 (en) 2005-09-15
JP4233214B2 (ja) 2009-03-04
PT1019507E (pt) 2004-06-30
KR20010024213A (ko) 2001-03-26
HUP0003563A3 (en) 2005-11-28
NZ503235A (en) 2002-08-28
EP1439231A3 (fr) 2004-12-22
ES2218860T3 (es) 2004-11-16
HK1032425A1 (en) 2001-07-20
KR20010024214A (ko) 2001-03-26
DE69823218T2 (de) 2004-08-26
US20050164936A1 (en) 2005-07-28
KR100560275B1 (ko) 2006-03-10
ATE263242T1 (de) 2004-04-15
CN1271385A (zh) 2000-10-25
HU226414B1 (en) 2008-11-28
IL135351A (en) 2006-08-20
CN1145693C (zh) 2004-04-14
EP1021541B1 (fr) 2004-04-14
CN1490049A (zh) 2004-04-21
DE69838188D1 (de) 2007-09-13
JP4230659B2 (ja) 2009-02-25
US6905676B2 (en) 2005-06-14
PL197569B1 (pl) 2008-04-30
EA003942B1 (ru) 2003-10-30
DK1019507T3 (da) 2004-07-19
AU750341B2 (en) 2002-07-18
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
HUP0003505A3 (en) 2005-11-28
KR100542934B1 (ko) 2006-01-11
PT1439231E (pt) 2007-08-20
SK286439B6 (sk) 2008-10-07
CA2305017A1 (fr) 1999-04-08
EE200000151A (et) 2001-02-15
HK1062637A1 (en) 2004-11-19
DK1021541T3 (da) 2004-08-02
CZ20001146A3 (cs) 2000-09-13
AU9442098A (en) 1999-04-23
SK4502000A3 (en) 2000-09-12
BG104267A (en) 2000-11-30
NZ503234A (en) 2002-06-28
EP1439231A2 (fr) 2004-07-21
CZ20001147A3 (cs) 2000-09-13
US6977071B2 (en) 2005-12-20
PT1021541E (pt) 2004-07-30
CN1233415C (zh) 2005-12-28
HU226468B1 (en) 2008-12-29
US7326411B2 (en) 2008-02-05
PL339545A1 (en) 2000-12-18
NO20001584L (no) 2000-03-27
EP1019507A1 (fr) 2000-07-19
EP1439231B1 (fr) 2007-08-01
DE69822856T2 (de) 2004-08-19
UA73080C2 (en) 2005-06-15
EP1021541A1 (fr) 2000-07-26
WO1999016877A1 (fr) 1999-04-08
EP1019507B1 (fr) 2004-03-31
AR013529A1 (es) 2000-12-27
EP0906954A1 (fr) 1999-04-07
DE69838188T2 (de) 2007-11-22
BR9812394A (pt) 2000-09-12
IL135352A (en) 2006-08-20
HK1032426A1 (en) 2001-07-20
PL196427B1 (pl) 2008-01-31
UA73081C2 (en) 2005-06-15
NO20001609D0 (no) 2000-03-28
ATE368742T1 (de) 2007-08-15
HUP0003505A2 (hu) 2001-02-28
US20030124677A1 (en) 2003-07-03
SK4512000A3 (en) 2000-09-12
CA2304827A1 (fr) 1999-04-08
CN1271386A (zh) 2000-10-25
EA200000378A1 (ru) 2000-10-30
CZ299479B6 (cs) 2008-08-06
NO20001609L (no) 2000-03-28
JP2001518296A (ja) 2001-10-16
US20050220790A1 (en) 2005-10-06
BG64679B1 (bg) 2005-11-30
CY1110927T1 (el) 2015-06-10
JP2001518297A (ja) 2001-10-16
WO1999016876A1 (fr) 1999-04-08
EA200000379A1 (ru) 2000-10-30
BR9812565A (pt) 2000-08-01
ES2215324T3 (es) 2004-10-01
ATE264390T1 (de) 2004-04-15
US20030119148A1 (en) 2003-06-26
EE200000152A (et) 2001-02-15
BG104266A (en) 2000-11-30
ES2287601T3 (es) 2007-12-16
PL339559A1 (en) 2000-12-18
BG64757B1 (bg) 2006-02-28
CZ299478B6 (cs) 2008-08-06
HUP0003563A2 (hu) 2001-02-28
EP0905241A1 (fr) 1999-03-31
EP0905240A1 (fr) 1999-03-31
US7338653B2 (en) 2008-03-04
DE69823218D1 (de) 2004-05-19
NO20001584D0 (no) 2000-03-27
DE69822856D1 (de) 2004-05-06
EA003940B1 (ru) 2003-10-30
AU9747498A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
ZA988675B (en) Amino-terminally truncated rantes as chemokine antagonists.
ZA977011B (en) Muscarinic antagonists.
AU3633997A (en) Chemokine receptor antagonists
AU5603094A (en) N,n-diacylpiperazine tachykinin antagonists
ZA981467B (en) Catalyst composition.
ZA9811407B (en) Crystalline teriparatide.
HK1030387A1 (en) Shank fitting structure.
EP0621648A3 (fr) Electrode.
ZA975261B (en) Composition.
EP0663827A4 (fr) Antagonistes recepteurs d'oxytocine tocolytique.
EP0684823A4 (fr) Antagonistes des recepteurs de fibrinogene.
AU4251197A (en) Therapeutic chemokine antagonists
HUP9903590A3 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA9811502B (en) Novel composition.
MXPA01012165A (es) Antagonistas ccr3 del receptor de quimiocina.
EP0625591A3 (fr) Electrolyseur.
ZA979670B (en) Piperazino derivatives as neurokinin antagonists.
ZA97928B (en) Novel heteroaryl-oxazolidinones.
ZA988586B (en) Truncated cellulase compositions.
ZA971184B (en) Endothelin antagonists.
EP0609198A3 (en) Electrode arrangement.
EP0651591A3 (fr) Système d'électrodes.
ZA987B (en) Substituted 4-benzoylpyrazoles.